Amidated Peptides vs Free Acids: Terminal Chemistry and Analytical Identification

A C-terminally amidated peptide ends in a primary carboxamide group, -C(=O)NH2, commonly written as -NH2 in peptide sequence notation. A free-acid peptide ends in a carboxyl group, -C(=O)OH, commonly written as -OH. For otherwise identical structures, the primary amide has a neutral monoisotopic mass approximately 0.984016 daltons lower than the free acid.

These are different covalent structures, not alternative names for a salt form. In nonclinical laboratory research, terminal chemistry should be specified separately from sequence, counter-ion composition, chromatographic purity, and peptide content.

Distinguishing the two terminal forms

Peptide sequences are conventionally written from the N-terminus to the C-terminus. Read the terminal suffix together with the complete sequence and modification specification.

Structural and analytical differences between otherwise matching peptide amides and free acids

Feature	C-terminal amide	C-terminal free acid
Terminal group	-C(=O)NH2, a primary carboxamide	-C(=O)OH, a carboxylic acid
Common sequence suffix	Peptide-NH2	Peptide-OH or peptide-COOH
Terminal charge near pH 7	Normally uncharged	Usually approximately -1, as -COO−
Neutral monoisotopic mass	Approximately 0.984016 Da lower than the matching acid	Approximately 0.984016 Da higher than the matching amide
Meaning of the designation	A covalent terminal modification	An unamidated terminal carboxyl group
Not established by the designation	Salt form, whole-peptide charge, purity, or assay behavior	Salt form, solution pH, purity, or assay behavior

An uncharged terminal amide does not make the whole peptide neutral. Likewise, “free acid” does not mean that the supplied material is free of counter-ions. Neither terminal designation, nor a chromatographic purity percentage, independently verifies the identity of a batch.

Reading -NH2 and -OH in a sequence

At the C-terminal end of standard sequence notation, -NH2 indicates that the final residue's carboxyl group is amidated. The suffix -OH indicates a free carboxyl functionality. Neither suffix represents an additional amino-acid residue.

For example, H-Ala-Gly-OH and H-Ala-Gly-NH2 both contain alanine followed by glycine, but their terminal groups differ. In these structural teaching examples, H- denotes an unmodified amino end.

Position matters: NH2 at the beginning of a structural formula can denote a free amino group rather than a terminal carboxamide. Ordinary peptide bonds within the chain are also amide bonds, but “C-terminally amidated” refers specifically to the end group.

Does -OH indicate a terminal alcohol?

Not in standard peptide sequence shorthand. The terminal -OH completes -C(=O)OH; it does not indicate conversion to an alcohol. If a label is ambiguous, request the full structure rather than inferring terminal chemistry from an isolated suffix.

Terminal chemistry and charge

Near neutral pH, a free C-terminal carboxyl group is usually predominantly deprotonated and negatively charged, whereas a primary C-terminal amide is normally uncharged. Amidation therefore generally makes an otherwise identical peptide approximately one charge unit more positive. This does not necessarily make the overall molecule positively charged.

As a simplified charge-accounting example, a peptide with a free amino end and no ionizable side chains can have an amino-terminal contribution of roughly +1 and a carboxyl-terminal contribution of roughly -1 near pH 7. Amidating the carboxyl end removes that terminal negative charge. This is an approximation, not a measured charge for every peptide.

The whole molecule's charge depends on sequence, all ionizable groups, other modifications, and solution pH. At sufficiently low pH, a free-acid terminus becomes predominantly protonated as -COOH, but it does not become an amide.

The substitution also changes local hydrogen-bonding chemistry. Terminal structure alone does not predict solubility, chromatographic retention, binding measurements, or stability. Those properties require measurements for the specified molecule under defined laboratory conditions.

Calculating the mass difference

Replacing the terminal -OH of a free acid with -NH2 adds one nitrogen atom and one hydrogen atom and removes one oxygen atom. The resulting primary amide has a neutral monoisotopic mass approximately 0.984016 Da lower than the acid.

A dalton, abbreviated Da, is a molecular mass unit. Monoisotopic mass uses specified isotopes rather than natural-abundance-weighted average atomic masses.

• Free acid to primary amide: subtract approximately 0.984016 Da.
• Primary amide to free acid: add approximately 0.984016 Da.
• The comparison requires an unchanged sequence and unchanged covalent features elsewhere in the molecule.
• The difference concerns the neutral peptide, not associated counter-ions, water, or other components of the supplied material.

For the teaching pair H-Ala-Gly-OH and H-Ala-Gly-NH2, the calculated neutral monoisotopic masses are approximately 146.0691 Da and 145.0851 Da, respectively. These are structural calculations, not analytical results for an Alpha Carbon Labs batch.

Interpreting mass spectra

Mass spectra report mass-to-charge ratio, m/z. For otherwise matching ions with the same adduct type and charge state, the acid-versus-amide separation is approximately 0.4920 m/z at charge +2 and 0.3280 m/z at charge +3.

Before comparing a report with a specification, establish whether the reported value is neutral monoisotopic mass, charged-ion m/z, or average molecular weight. These quantities are not interchangeable.

A matching overall mass supports an identity assignment but does not locate every modification. Rounded molecular-weight values may not distinguish the acid from the amide. Where terminal identity remains uncertain, additional structural evidence is needed rather than an assignment based only on the product name or nominal mass.

Scope of the amidation literature

In laboratory enzyme experiments using pituitary-derived preparations, Bradbury and colleagues investigated C-terminal amide formation. Eipper and colleagues identified activity in pituitary preparations acting on glycine-extended peptides and requiring molecular oxygen, copper, and ascorbic acid. These findings concern experimentally studied enzyme preparations, not human clinical outcomes or tests of Alpha Carbon Labs materials. [1,2]

Merkler's review discusses in-vitro enzymatic production of amidated peptides and the peptide-dependent significance of the terminal amide. Prigge and colleagues review structural and mechanistic laboratory research on copper monooxygenases and peptide amidation. These reviews do not constitute a single model or a controlled comparison establishing uniform behavior across peptide sequences. [3,4]

For an acid-versus-amide laboratory comparison, treat the variants as separate compounds. Match the remaining sequence, other modifications, counter-ion specifications, peptide-content basis, and assay conditions. Measure the endpoint of interest rather than assuming a general activity or stability advantage.

Published structural examples

In the in-vitro receptor-characterization work reported by Kotani and colleagues, kisspeptin-10 is described with a C-terminal amide. That structural feature distinguishes it from a matching free-acid analog. [5] When reviewing the KissPeptin-10 listing, assess the stated terminal group and batch documentation separately: the publication does not verify the identity or assay behavior of a supplied lot.

Raun and colleagues studied ipamorelin in in-vitro rat pituitary cell assays and in animal experiments involving rats and swine. The published peptide structure contains a terminal amide. [6] Evaluate the Ipamorelin listing against its own structural specification and batch-specific analytical documentation; those published experiments do not validate a supplied lot.

These structural examples show why an amino-acid list without terminal chemistry can be an incomplete identity specification. They do not establish a general ranking of acids and amides or transfer published findings to Alpha Carbon Labs products.

Terminal chemistry is separate from salt form

Amidation changes atoms covalently bonded into the peptide. A salt-form designation describes associated ions. “C-terminal amide” and “acetate salt” can therefore describe the same material because they address different aspects of its composition.

A free-acid peptide can also have a salt-form designation when other groups carry charge. “Free acid” identifies the terminal carboxyl functionality; it does not certify the absence of associated ions in the preparation.

Record terminal chemistry and counter-ion composition in separate specification fields. For related in-vitro assay considerations, see the peptide counter-ion selection guide.

pH adjustment does not produce a terminal amide

Ordinary dissolution or pH adjustment does not convert a free-acid peptide into an amidated peptide. Interconversion between -COOH and -COO− transfers a proton. Formation of -CONH2 requires a chemical or enzymatic transformation of the covalent structure.

In solid-phase peptide synthesis, resin and linker chemistry help determine the C-terminal group obtained after cleavage. Rink-amide supports are commonly used to prepare peptide amides, whereas Wang-type supports commonly yield peptide acids. Terminal chemistry should be specified as part of the target structure, not inferred from an assay solution's pH.

The papers by Rink and Wang report experimental chemical synthesis using resin systems for protected peptide fragments; they are not clinical, animal, or in-silico studies. [7,8] When discussing a target laboratory structure through the peptide synthesis information, state the required terminal group explicitly.

Checklist for specifying research material

1. Write the complete N-to-C sequence. Identify stereochemistry, D-amino acids, and unusual residues explicitly.
2. Name the C-terminal group. Specify “primary amide, -C(=O)NH2” or “free carboxyl group, -COOH/-COO− depending on pH.” Avoid an undefined “standard form.”
3. Specify the N-terminus independently. Distinguish a free amino end from an acetylated end or another modification.
4. List other covalent features. Include disulfide connectivity, cyclization, lipid attachments, and labels where applicable.
5. Record salt form or counter-ion composition separately. A counter-ion name does not identify terminal chemistry.
6. State the mass convention. Request the neutral peptide formula and distinguish monoisotopic mass from average molecular weight.
7. Clarify the quantity basis. Distinguish net peptide content from total material mass. Chromatographic purity is not a peptide-content measurement.
8. Match documentation to the lot. Confirm that identity results and the certificate of analysis refer to the specified structure and supplied batch.

Specification template

Sequence

Complete N-to-C sequence, including stereochemistry and unusual residues.

N-terminus

Free amino group, acetylated group, or another specified structure.

C-terminus

Primary amide -C(=O)NH2 or free carboxyl group -C(=O)OH.

Other covalent modifications

None, or a complete list with relevant connectivity.

Salt form or counter-ion

Composition specified independently of terminal chemistry.

Quantity basis

Net peptide content or total material mass, with the measurement basis identified.

Identity documentation

Molecular formula, calculated mass convention, and batch-specific analytical results.

If a quotation or specification omits terminal chemistry, resolve that omission before accepting the structural assignment.

Checking analytical documentation

Look for agreement among the written structure, molecular formula, calculated mass, and batch-specific identity data. A high chromatographic purity percentage cannot distinguish the intended compound from a highly pure but incorrect terminal variant.

When reviewing certificate-of-analysis documents, check whether the formula and mass calculation include the stated terminal group. Identical formulas or identical high-precision neutral masses for otherwise matching acid and amide variants require clarification.

Mass measurements need sufficient resolution and appropriate interpretation for the identity question. If the terminal assignment remains ambiguous, request clarification or additional structural analysis.

Use the quality-control information to frame specific questions: which structure was expected, what was measured, and what does the result establish? A method description is not itself a result for a particular lot.

Frequently asked questions

Does NH2 always mean C-terminal amidation?

No. Position and notation matter. At the C-terminal end of standard peptide notation it normally denotes a terminal amide; elsewhere it can denote an amino group. Confirm the full terminal structure, -C(=O)NH2.

Is a free-acid peptide necessarily negative overall?

No. The terminal carboxyl group is usually negative near neutral pH, but the total charge also depends on other ionizable groups. The whole peptide can be positive, negative, or approximately neutral.

Can an amidated peptide also be an acetate salt?

Yes. A C-terminally amidated peptide can contain positively charged groups associated with acetate counter-ions. The terminal group and counter-ion describe separate aspects of the material.

Can the matching acid and amide be substituted in an experiment?

Such a substitution changes the specified compound. For replication, match the documented terminal chemistry. Treat an intentional acid-versus-amide substitution as a separate experimental comparison.

Does amidation establish storage or handling requirements?

No. The terminal label alone establishes neither storage stability nor hazard classification. Consult the material-specific safety data sheet, storage instructions, and applicable laboratory procedures rather than inferring handling requirements from -NH2 or -OH.

References

1. [1] Bradbury AF, Finnie MDA, Smyth DG. Mechanism of C-terminal amide formation by pituitary enzymes. Nature. 1982;298:686–688.
2. [2] Eipper BA, Mains RE, Glembotski CC. Identification in pituitary tissue of a peptide alpha-amidation activity that acts on glycine-extended peptides and requires molecular oxygen, copper, and ascorbic acid. Proceedings of the National Academy of Sciences of the USA. 1983;80:5144–5148.
3. [3] Merkler DJ. C-terminal amidated peptides: production by the in vitro enzymatic amidation of glycine-extended peptides and the importance of the amide to bioactivity. Enzyme and Microbial Technology. 1994;16:450–456.
4. [4] Prigge ST, Mains RE, Eipper BA, Amzel LM. New insights into copper monooxygenases and peptide amidation: structure, mechanism and function. Cellular and Molecular Life Sciences. 2000;57:1236–1259.
5. [5] Kotani M, et al. The metastasis suppressor gene KiSS-1 encodes kisspeptins, the natural ligands of the orphan G protein-coupled receptor GPR54. Journal of Biological Chemistry. 2001;276:34631–34636.
6. [6] Raun K, et al. Ipamorelin, the first selective growth hormone secretagogue. European Journal of Endocrinology. 1998;139:552–561.
7. [7] Rink H. Solid-phase synthesis of protected peptide fragments using a trialkoxy-diphenyl-methylester resin. Tetrahedron Letters. 1987;28:3787–3790.
8. [8] Wang SS. p-Alkoxybenzyl alcohol resin and p-alkoxybenzyloxycarbonylhydrazide resin for solid phase synthesis of protected peptide fragments. Journal of the American Chemical Society. 1973;95:1328–1333.

Limitations: Alpha Carbon Labs materials are intended solely for nonclinical laboratory research. Published findings do not establish the safety, effectiveness, approval, or suitability of the material sold for human or veterinary use.